Orphan designation: tazemetostat Treatment of diffuse large B-cell lymphoma, 21/03/2018 Withdrawn | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 18 May 2026 - 10:43

Orphan designation: tazemetostat Treatment of diffuse large B-cell lymphoma, 21/03/2018 Withdrawn

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2004

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters